Camurus announces positive results from the phase IIb POSITANO study, showing that CAM2029 significantly reduces liver and cyst volume in patients with polycystic liver disease (PLD). The study met its primary endpoint with a 4,3 percent reduction in length-adjusted liver volume and 8,7 percent in cyst volume compared to placebo, as well as improved symptoms. CAM2029 was well tolerated with no new safety concerns. Camurus plans to discuss a Phase III study with regulatory authorities.
Camurus CAM2029 shows efficacy in polycystic liver disease
Notes
Mentice consolidates operations to Denver
Bio-Works secures million-dollar order from global pharmaceutical company
OncoZenge receives investment proceeds from Yangtian Bio-Pharmaceutical
Xspray Pharma confirms bioequivalence for XS003
Evaxion converts debt of EUR 3,5 million
NEWSLETTER
NEWS
AI-designed proteins are created in seconds
The price of Leqembi needs to be lowered in Japan
Merck gears up in lung diseases with giant acquisition
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
